ICG-001 | 2275

A specific inhibitor of Wnt/β-catenin signaling pathway. It down-regulates beta-catenin/T cell factor signaling by specifically binding to cyclic AMP response element-binding protein (CBP). ICG-001 selectively induces apoptosis in transformed cells but not in normal colon cells, reduces in vitro growth of colon carcinoma cells, and is efficacious in the Min mouse and nude mouse xenograft models of colon cancer.

ICG-001 is a specific inhibitor of Wnt/β-catenin signaling pathway. It down-regulates beta-catenin/T cell factor signaling by specifically binding to cyclic AMP response element-binding protein (CBP)

2275 | ICG-001 DataSheet

Alternate Name/Synonyms: (6S,9aS)-Hexahydro-6-[(4-hydroxyphe­nyl)methyl]-8-(1-naphthalenylmethyl)-4,7-dioxo-N-(­phenylmethyl)-2H-pyrazino[1,2-a]pyrimidine-1(6H)-c­arboxamide

Appearance: White solid

Formulation: N/A

CAS Number: 847591-62-2

Structure Available?: Yes

Peptide sequence: N/A

Salt Form: No

Molecular Formula: C₃₃H₃₂N₄O₄

Molecular Weight: 548.63

Cell-Permeable?: Yes

Purity: ≥98% by HPLC

Solubilities: DMSO (~50 mg/ml) or EtOH (~25 mg/ml)

Handling: Protect from air and moisture

Country of Origin: USA

Tag Line: A specific inhibitor of Wnt/β-catenin signaling pathway

MDL Number: N/A

PubChem CID: 11238147

SMILES: C1CN(C2CN(C(=O)C(N2C1=O)CC3=CC=C(C=C3)O)CC4=CC=CC5=CC=CC=C54)C(=O)NCC6=CC=CC=C6

InChi: InChI=1S/C33H32N4O4/c38-27-15-13-23(14-16-27)19-29-32(40)35(21-26-11-6-10-25-9-4-5-12-28(25)26)22-30-36(18-17-31(39)37(29)30)33(41)34-20-24-7-2-1-3-8-24/h1-16,29-30,38H,17-22H2,(H,34,41)/t29-,30+/m0/s1

InChi Key: HQWTUOLCGKIECB-XZWHSSHBSA-N